사설 바카라 Biotech’s knee osteoarthritis treatment 'OSCA' demonstrates 12-month efficacy from a single Injection
사설 바카라 1 clinical trial long-term follow-up confirms cartilage regeneration and pain relief, raising expectations for 사설 바카라 2a trial success
[by Sung, Jae Jun] 사설 바카라 Biotech announced on May 29 that its knee osteoarthritis treatment candidate, 'OSCA', demonstrates improved therapeutic effects lasting 12 months with a single injection in the Phase 1 clinical trial. Based on these results, the company stated that the possibility of success in the ongoing Phase 2a clinical trial has been further increased.
According to 사설 바카라 Biotech, a 12-month long-term follow-up MRI analysis of participants in the Phase 1 clinical trial confirmed cartilage regeneration and restoration of damaged subchondral bone in a significant number of patients receiving medium and high doses. Notably, all patients in the high-dose group exhibited overall improvements in cartilage degradation, structural abnormalities, edema, synovitis, and meniscal damage. Furthermore, the company reported an improvement in patients’ quality of life, attributed to the relief of severe pain symptoms.
"We confirmed the potential for long-term therapeutic efficacy, as the treatment effects observed at six months were sustained or further improved over time," said Bae Yohan, Executive Managing Director of Clinical Development Division at 사설 바카라 Biotech. "Consequently, patient enrollment for the Phase 2a clinical trial is progressing rapidly, and the prospects for collaboration with global markets and partners have also increased," he added.